Profilo mutazionale degli oncogeni EGFR e KRAS in cellule di carcinoma broncogeno non-a-piccole cellule ottenute da Fine needle aspiration cytology (FNAC)

摘要: Cancer is a genetic disease and this concept has now been widely exploited by both biologists clinicians to design new targeted therapeutical approaches. Indeed many data have already allowed us ameliorate not only our knowledge about cancer onset, but also patient treatment. Correlation between mutations in alleles drug response crucial point identify drugs or combinations that match the profile of individual tumors. On other hand, experiences derived from receptor tyrosine kinases (RTKs) inhibition pointed out treatment really successful small subset The latter are eventually addicted alterations responsible for receptors activation continued expression their signaling pathways. Therefore, switching off oncogenic activity specific inhibitors will trigger an “oncogenic shock” which lead tumor cell die. Overall these observations provide strong rationale molecular-based diagnosis patients selection Understanding how mutational status affects sensibility resistance represents most potential strategy identifying effective personalized therapies. In consideration high incidence poor prognosis affected patients, lung carcinoma considered still major objective therapeutic approach. Experiences disease, mainly non-small (NSCLC), represent fundamental achievement translational research. From perspective, members EGFR signal transduction pathway play key role carcinogenesis act as markers predictive anti-EGFR therapy. unselected NSCLCs activating rarely present (10%); mutation frequency increases over 50% restricted NSCLC patients: East-Asian, women, non smokers, ADC (mainly BAC variant). Moreover up 77% among TKIs responders, while it 7% unsensitive cases. This project aims evaluate cohort prevalence KRAS genes analyzing cells obtained through transthoracic biopsy FNAC, actually appropriate diagnostic tool peripheral lesions, such ADKs account 40% diagnosis. Validation sequencing technology on samples constituted few two relevant implications. First might allows routinary molecular profiling powerful integration conventional histo-pathological Besides clinical management take advantages characterization EGFR-KRAS order develop strategies.